Unipolar-voltage-based evaluation of left atrial tissue properties and ablation outcome in patients with atrial fibrillation
Europace · 2023
DOI: 10.1093/europace/euad240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2023. Verfasst von Masashi Kamioka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke 329-0498, Japa…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Atrial Appendage, Catheter Ablation, Pulmonary Veins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
The relationship between local unipolar voltage (UV) in the pulmonary vein (PV)-ostia and left atrial wall thickness (LAWT) and the utility of these parameters as indices of outcome after atrial fibrillation (AF) ablation remain unclear. Methods and results Two-hundred seventy-two AF patients who underwent AF ablation were enrolled. Unipolar voltage of PV-ostia was measured using a CARTO system, and LAWT was measured using computed tomography. The primary endpoint was atrial tachyarrhythmia (ATA) recurrence including AF. The ATA recurrence was documented in 74 patients (ATA-Rec group). The UV and LAWT of the bilateral superior PV roof to posterior and around the right-inferior PV in the ATA-Rec group were significantly greater than in patients without ATA recurrence (ATA-Free group) (P < 0.001). The UV had a strong positive correlation with LAWT (R2 = 0.446, P < 0.001). The UV 2.7 mV and the corresponding LAWT 1.6 mm were determined as the cut-off values for ATA recurrence (P < 0.001, respectively). Multisite LA high UV (HUV, ≥4 areas of >2.7 mV) or multisite LA wall thickening (≥5 areas of >1.6 mm), defined as LA hypertrophy (LAH), was related to higher ATA recurrence. Among 92 LAH patients, 66 had HUV (LAH-HUV) and the remaining 26 had low UV (LAH-LUV), characterized by history of non-paroxysmal AF and heart failure, reduced LV ejection fraction, or enlarged LA. In addition, LAH-LUV showed the worst ablation outcome, followed by LAH-HUV and No LAH (log-rank P < 0.001).
Conclusion
Combining UV and LAWT enables us to stratify recurrence risk and suggest a tailored ablation strategy according to LA tissue properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.
- Department of Arrhythmia and Cardiac Pacing, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
- Cardiovascular Center, Ohta Nishinouchi Hospital, 2-5-20 Nishinouchi, Koriyama 963-8558, Japan.
ORCID-Profile: Masashi Kamioka, Hisaki Makimoto, Tomonori Watanabe, Hiroaki Watanabe, Takashi Kaneshiro, Naoko Hijioka, Takahiro Komori, Tomoyuki Kabutoya, Kazuomi Kario
Zitieren
APA
Kamioka, M., Makimoto, H., Watanabe, T., Watanabe, H., Okuyama, T., Kaneshiro, T., Hijioka, N., Yokota, A., Komori, T., Kabutoya, T., Imai, Y., & Kario, K. (2023). Unipolar-voltage-based evaluation of left atrial tissue properties and ablation outcome in patients with atrial fibrillation. Europace. https://doi.org/10.1093/europace/euad240
Vancouver
Kamioka M, Makimoto H, Watanabe T, Watanabe H, Okuyama T, Kaneshiro T, et al. Unipolar-voltage-based evaluation of left atrial tissue properties and ablation outcome in patients with atrial fibrillation. Europace. 2023. doi:10.1093/europace/euad240
BibTeX
@article{Kamioka2023,
author = {Kamioka, Masashi and Makimoto, Hisaki and Watanabe, Tomonori and Watanabe, Hiroaki and Okuyama, Takafumi and Kaneshiro, Takashi and Hijioka, Naoko and Yokota, Ayako and Komori, Takahiro and Kabutoya, Tomoyuki and Imai, Yasushi and Kario, Kazuomi},
title = {Unipolar-voltage-based evaluation of left atrial tissue properties and ablation outcome in patients with atrial fibrillation},
journal = {Europace},
year = {2023},
doi = {10.1093/europace/euad240}
}
EUVIMED